Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Recently, a pediatric case prompted inquiry into the use of peptides, including BCP-157, to accelerate recovery from an overuse injury in a 12-year-old athlete
Genome-wide estimate of the heritability of multiple system atrophy
And your peptide protocol is part of a larger treatment strategy that may include hormone optimization, IV therapy, nutritional support, and other therapies working together
Generally, B12 injections are safe when given by a healthcare professional
In the school w e perceive those generation-linked changes that so often upset our assumptions about the lines along which society is going to develop, and prove them to be wrong